

May 16, 2026

To,

Listing / Compliance Department,  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (East), Mumbai - 400 051  
NSE Symbol: VALIANTLAB

Listing / Compliance Department,  
BSE Limited  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001  
BSE Scrip Code: 543998

Dear Sir/Madam,

**Subject: Press Release - Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

Pursuant to Regulation 30 of Listing Regulations, we wish to inform you that the Board of Directors of the Company, at their meeting held on **Saturday, May 16, 2026** has considered exploring potential restructuring options amongst the Company, its holding, subsidiaries and associates, with a view to, *inter-alia*, achieving operational, organizational and strategic synergies.

In this regard, please find enclosed the press release issued by the Company titled: **"Valiant Laboratories Limited Announces Evaluation of Restructuring Options"**

The Board meeting concluded at 5:03 p.m.

You are requested to kindly take the same on record.

Yours faithfully,

For **Valiant Laboratories Limited**

**Akshay Gangurde**  
Company Secretary & Compliance Officer

*Encl: As above*



## **VALIANT LABORATORIES LIMITED ANNOUNCES EVALUATION OF RESTRUCTURING OPTIONS**

The Board of Directors of Valiant Laboratories Limited (VLL) has accorded its in-principle approval to explore potential restructuring options amongst VLL, its holding, subsidiaries and associates, with a view to *inter-alia* achieving operational, organizational and strategic synergies, and incidental commercial objectives, which may be implemented through one or more tranches, transactions or arrangements, including amalgamation, merger, demerger, transfer, reorganization or any other similar arrangement, in such sequence, combination and manner as may be considered commercially expedient, subject to applicable law and requisite approvals.

The broad strategic objectives that the Board has identified as guiding principles for the aforesaid evaluation include, among others:

- Unlocking long-term value for shareholders and other stakeholders through simplification of the existing structure;
- Creating strategically aligned business platforms better positioned to capitalize on distinct market opportunities;
- Enhancing clarity of business and investment profiles to facilitate improved stakeholder understanding and wider investor participation;
- Sharpening strategic focus on core competencies through suitable realignment and optimization of business and resources, with a view to enhancing efficiency and realizing operational and structural synergies; and
- Exploring tax-efficient and compliant structures that support the above objectives and mitigate complexity in future corporate actions.

The matter will be further evaluated, and the Board of Directors will be apprised of the outcomes for its consideration, following which it shall determine the future course of action, if any, as it may deem appropriate. Appropriate announcements and public disclosures, as may be required in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, will be made from time to time.

**For further information, please contact:**

**Mr. Akshay Gangurde**  
Company Secretary & Compliance Officer  
Contact Number: 022 - 49712001/220/221  
Email ID: [investor@valiantlabs.in](mailto:investor@valiantlabs.in)

**[www.valiantlabs.in](http://www.valiantlabs.in) | CIN : L24299MH2021PLC365904**

**Registered Office:** 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080.  
**T:** 022-49717221/49712001/49717220 | **E:** [investor@valiantlabs.in](mailto:investor@valiantlabs.in)



## **About the Company**

With over 45+ years of excellence, Valiant Laboratories Limited is a premier Indian API manufacturer. VLL's origin dates back to 1980 when it began operations as Bharat Chemicals, producing Para Nitro Phenol, an essential compound used in pharmaceuticals, fungicides and rubber additives. Following years of dedicated R&D, VLL has transitioned into pharmaceutical manufacturing with the introduction of Paracetamol API. Today, the Company operates from its strategically positioned manufacturing facility in Tarapur, dedicated to manufacturing various grades and sizes of Paracetamol API.

For a better understanding of the business, please refer to the company's website at <https://www.valiantlabs.in>.

*This press release is issued for informational purposes only and contains forward-looking statements that involve risks and uncertainties. The initiation of this evaluation process does not constitute a commitment by the Company to implement any restructuring. The Company reserves the right to abandon, modify or defer any proposed course of action at any stage.*

**[www.valiantlabs.in](http://www.valiantlabs.in) | CIN : L24299MH2021PLC365904**

**Registered Office:** 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080.

**T:** 022-49717221/49712001/49717220 | **E:** [investor@valiantlabs.in](mailto:investor@valiantlabs.in)